Evaluation of reaction and adverse events in Trichuris suis ova therapy
Phase 1
- Conditions
- Healthy adult
- Registration Number
- JPRN-UMIN000028248
- Lead Sponsor
- The Jikei University School of Medicine Department of Tropical Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Male
- Target Recruitment
- 12
Inclusion Criteria
Not provided
Exclusion Criteria
A person who previously administered TSO and had severe adverse events. One who was judged inappropriate by the attending physician.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Frequency of adverse events during 56 days after administration of single dose of Trichuris suis ova.
- Secondary Outcome Measures
Name Time Method Frequency of infection by T. suis on day 56 after administration of single dose of T. suis ova.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What immune modulation mechanisms does Trichuris suis ova therapy induce in phase I trials for healthy adults?
How does Trichuris suis ova therapy compare to standard-of-care treatments for parasitic infection-related immune modulation?
What biomarkers predict adverse events in JPRN-UMIN000028248 Trichuris suis ova therapy trial?
What are the long-term management strategies for adverse events in helminth-based therapies like Trichuris suis ova?
Are there combination therapies with Trichuris suis ova and other helminths for immune regulation in clinical trials?